New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten adults

The AstraZeneca CaReMe CKD is one of the largest and most contemporary real-world studies estimating the prevalence, outcomes and cost of CKD in over 2.4 million CKD patients from 9 countries from Europe, plus Israel and Canada

Data highlight the high burden of disease on patients and healthcare systems and urgent need to improve early screening, diagnosis and treatment intervention

CKD is a progressive disease that can eventually lead to kidney failure and premature mortality